Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 29,131 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $68.61, for a total transaction of $1,998,677.91. Following the sale, the executive vice president now directly owns 73,330 shares of the company’s stock, valued at approximately $5,031,171.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Azelby also recently made the following trade(s):

  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36.
  • On Thursday, November 2nd, Robert Azelby sold 6,666 shares of Juno Therapeutics stock. The stock was sold at an average price of $54.95, for a total transaction of $366,296.70.

Juno Therapeutics Inc (NASDAQ JUNO) opened at $67.81 on Friday. Juno Therapeutics Inc has a 1-year low of $19.07 and a 1-year high of $74.35. The company has a market cap of $8,148.52, a price-to-earnings ratio of -20.06 and a beta of 2.32. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the prior year, the company posted ($0.57) earnings per share. The firm’s revenue was up 115.4% on a year-over-year basis. analysts forecast that Juno Therapeutics Inc will post -4.02 EPS for the current fiscal year.

JUNO has been the subject of several research reports. Raymond James Financial increased their price objective on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Citigroup reissued a “buy” rating and set a $59.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Wells Fargo & Co downgraded shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Finally, Wedbush reissued an “outperform” rating and set a $64.00 price objective (up previously from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $47.26.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Juno Therapeutics by 2.1% during the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after purchasing an additional 131,864 shares during the last quarter. Capital International Investors acquired a new stake in Juno Therapeutics in the third quarter valued at $256,339,000. BlackRock Inc. lifted its stake in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock valued at $128,357,000 after acquiring an additional 110,503 shares during the last quarter. State Street Corp lifted its stake in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after acquiring an additional 222,754 shares during the last quarter. Finally, Capital World Investors lifted its stake in Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock valued at $72,483,000 after acquiring an additional 295,000 shares during the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Robert Azelby Sells 29,131 Shares of Juno Therapeutics Inc (JUNO) Stock” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2018/01/21/robert-azelby-sells-29131-shares-of-juno-therapeutics-inc-juno-stock.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.